Vitamin d derivative may help keep bones strong after menopause

NCT ID NCT07660536

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This trial investigates whether doxercalciferol, a form of vitamin D, can prevent bone loss in the spine and thigh bone in postmenopausal women with low bone density. Participants take either doxercalciferol or a placebo daily for two years, with bone density measured at the start, 12 months, and 24 months. The goal is to see if this drug can help maintain bone strength and reduce fracture risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

doxercalciferol

What this could lead to

If it works, this could point toward a non-hormonal option to slow bone loss and reduce fracture risk in postmenopausal women.

What could go wrong

This is a small, early-to-mid-stage trial. The drug may not improve bone density more than placebo, and side effects like elevated calcium levels are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS (SENILE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Creighton University Medical center

    Omaha, Nebraska, 68132, United States